Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal CancerGuruFocus · 14 hr ago
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal CancerGlobeNewsWire · 15 hr ago
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal CancerGuruFocus · 1 day ago
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal CancerGlobe News Wire · 1 day ago
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal CancerGuruFocus · 1 day ago
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian CancerBusiness Wire · 2 days agoGenmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | $0.37 | $0.54 | Beat |
| May 7, 2026 | $0.15 | $0.09 | Miss |
| Feb 17, 2026 | $0.46 | $0.05 | Miss |
| Nov 6, 2025 | $0.48 | $0.65 | Beat |
| Aug 7, 2025 | $0.39 | $0.54 | Beat |
| May 8, 2025 | $0.23 | $0.31 | Beat |